
## Khalad Maliyar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8281716/publications.pdf Version: 2024-02-01



ΚΗΛΙΛΟ ΜΛΙΙΥΛΟ

#	Article	IF	CITATIONS
1	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. Journal of the American Academy of Dermatology, 2020, 83, 579-586.	1.2	30
2	Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. Journal of Cutaneous Medicine and Surgery, 2020, 24, 588-595.	1.2	29
3	Modifications to dermatology residency education during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, e235-e236.	1.2	15
4	Genital Ulcer Disease: A Review of Pathogenesis and Clinical Features. Journal of Cutaneous Medicine and Surgery, 2019, 23, 624-634.	1.2	14
5	Reply to: "Skin damage among health care workers managing coronavirus disease 2019― Journal of the American Academy of Dermatology, 2020, 83, e169-e170.	1.2	10
6	Alopecia Areata Related Paradoxical Reactions in Patients on Dupilumab Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2021, 25, 451-452.	1.2	9
7	Drugs associated with development of pityriasis rubra pilaris: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1071-1081.	1.2	7
8	A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 598-615.	1.2	6
9	Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. Journal of the American Academy of Dermatology, 2020, 83, 1813-1814.	1.2	5
10	Treatment outcomes in confluent and reticulated papillomatosis: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 825-829.	1.2	5
11	Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 176-180.	1.2	5
12	A systematic review of eczematous eruptions in patients receiving biologic therapy. Journal of the American Academy of Dermatology, 2021, 85, 1630-1635.	1.2	5
13	Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review. JAAD International, 2021, 2, 1-4.	2.2	4
14	Biologic treatment in pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: A systematic review. Journal of the American Academy of Dermatology, 2021, 85, 1011-1013.	1.2	4
15	Development of morphea in patients receiving biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1081-1085.	1.2	3
16	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review. Journal of the American Academy of Dermatology, 2020, 85, 981-983.	1.2	2
17	Hair pull test: A clinical update for patients with Asian- and Afro-textured hair. Journal of the American Academy of Dermatology, 2021, 85, 1599-1601.	1.2	2
18	COVID-19 and wound care: A Canadian perspective. JAAD International, 2020, 1, 79-80.	2.2	2

KHALAD MALIYAR

#	Article	IF	CITATIONS
19	Hereditary haemorrhagic telangiectasia: A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110030.	0.3	1
20	A Brief History of Psoriasis Management in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 273-277.	1.2	1
21	Full Body Skin Examination Practices Among Canadian Dermatologists: Results of a Nationwide Survey. Journal of Cutaneous Medicine and Surgery, 2021, 25, 212-215.	1.2	1
22	Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 521-522.	1.2	1
23	Development of granuloma annulare in patients on biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 85, 1594-1597.	1.2	0
24	Development of dermatomyositis in patients on biologic therapy: A systematic review. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
25	Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature. Skin Therapy Letter, 2020, 25, 1-4.	0.3	0